Both the drugs, developed by US-based Arrowhead Pharmaceuticals, were found to significantly lower triglyceride levels in patients with mixed hyperlipidemia, a congenital disease in which an individual has naturally higher levels of cholesterol and fat in their body. These patients were already taking cholesterol-lowering drugs, known as statins.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/PtzVZUb
0 Comments